Table 1.
IHC scores for percentage of tumor cells staining positively for phospho-C-Met, and clinical data according to genotype
|
NRAS Mutant N (%) |
Wt/Wt N (%) |
BRAF Mutant N (%) |
|
|---|---|---|---|
| N | 13 | 11 | 13 |
| p-C-Met IHC score | |||
| 0 | 6 (46.2) | 2 (18.2) | 9 (69.2) |
| 1 | 1 (7.7) | 1 (9.1) | 2 (15.4) |
| 2 | 3 (23.1) | 5 (45.5) | 0 (0) |
| 3 | 3 (23.1) | 3 (27.3) | 2 (15.4) |
| Median age (yrs) | 52 | 54 | 46 |
| Gender | |||
| Male | 6 (46.1) | 7 (63.3) | 11 (84.6) |
| Female | 7 (53.8) | 4 (36.4) | 2 (15.4) |
| Histology | |||
| SS | 9 (69.2) | 7 (63.6) | 5 (38.5) |
| Nodular | 2 (15.4) | 4 (36.4) | 6 (46.2) |
| Lentigo | 1 (7.7) | 0 (0) | 0 (0) |
| Unclassified | 1 (7.7) | 0 (0) | 2 (15.4) |
| Median Breslow depth (mm) | 1.18 | 1.75 | 4.00 |
| Median Clark Level | 3 | 4 | 4 |
| Site (%) | |||
| Extremity | 12 (92.3) | 6 (54.5) | 3 (23.1) |
| Trunk | 1 (7.7) | 5 (45.5) | 8 (61.5) |
| Head/Neck | 0 (0) | 0 (0) | 2 (15.4) |
| Ulceration | |||
| yes | 1 (7.7) | 1 (9.1) | 6 (46.2) |
| no | 12 (92.3) | 10 (90.9) | 7 (53.8) |
| Solar Elastosis* | |||
| yes | 10 (76.9) | 8 (72.7) | 10 (83.3) |
| no | 3 (23.1) | 3 (27.3) | 2 (16.7) |
| Status | |||
| Alive, NED | 10 (76.9) | 7 (63.6) | 8 (61.5) |
| Dead of disease | 3 (23.1) | 4 (36.4) | 4 (30.8) |
| Dead, cause unknown | 0 (0) | 0 (0) | 1 (7.7) |
| AJCC Stage | |||
| 1 | 7 (53.8) | 5 (45.5) | 0 (0) |
| 2 | 4 (30.8) | 1 (9.0) | 3 (23.1) |
| 3 | 2 (15.4) | 5(45.5) | 10 (76.9) |
SS, superficial spreading; NED, no evidence of disease
*
One BRAF-mutated tumor was not evaluable for solar elastosis.